

No. PMBI/DRUG/RC-159/2021

Dated: 03.03.2022

ORDER

Pharmaceuticals and Medical Devices Bureau of India, New Delhi had published tender no. BPPI/DRUG/RC-159/2021 on 13.01.2021 through e-procurement process for supply of drugs.

2. Where M/s. Ravian Lifesciences Pvt. Ltd. participated in the above-mentioned tender and the firm was awarded with the rate contract of 2 years against Drug Code – 511 (Paracetamol Tablets IP 650mg) vide Letter of Award no. BPPI/DRUG/RC-159/2021/LoA-1 on 27.05.2021. However, the firm do not oblige the awarded rate contract for Drug Code 511. The details of rate contract awarded are as under: -

Sr. No	Drug Code	Drug Code and Name	Unit Size	Rate per Unit size exclusive of GST (Rs.)	Rate of GST in %	Rate per Unit size inclusive of GST (Rs.)
1	511	Paracetamol Tablets IP 650mg	15's	6.75	12	7.56

3. Accordingly, Pharmaceuticals and Medical Devices Bureau of India issued a Show Cause Notice dated 02.09.2021 to the tenderer informing about the tender provisions of clause no. 11.B, 18.Q, 26.H & 27.A of the published tender document to explain their part within 7 days why following actions shall not be taken against them: -

- (i) Forfeiture of performance security.
- (ii) Consider your bad performance for future dealings and disqualify your firm/company from participating in the tender for the next 2 years.
- (iii) Initiate blacklisting of your firm/company.

4. Whereas following the Show Cause Notice, the firm vide their letter dated 07.09.2021 informed about their inability to supply Drug Code 511 as per the awarded rate contract.

5. In view of the above-mentioned facts, according to the provisions of tender clause 26.H and 27.A the firm is being debarred for a period of 2 years to participate in the tender of PMBI for supply of drug i.e., **Drug Code: 511, Paracetamol Tablets IP 650mg** from the date of issuance of this order and liable for forfeiture of performance security deposit i.e., Rs. 4,76,280/- as per tender terms and conditions.

6. The order is without the prejudice to the legal and criminal action to be taken if any, by Pharmaceuticals and Medical Devices Bureau of India, New Delhi in the matter.



Ravi Dadhich, DANICS
Chief Executive Officer
Pharmaceuticals and Medical Devices Bureau of India
New Delhi